Inactive Instrument

Tricida, Inc.

Equities

TCDA

US89610F1012

Biotechnology & Medical Research

Tricida, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 09, 2021 at 04:05 pm

Tricida, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 29.331 million compared to USD 57.175 million a year ago. Net loss was USD 33.553 million compared to USD 58.170 million a year ago. Basic loss per share from continuing operations was USD 0.67 compared to USD 1.16 a year ago. For the half year, operating loss was USD 71.401 million compared to USD 130.082 million a year ago. Net loss was USD 86.915 million compared to USD 132.284 million a year ago. Basic loss per share from continuing operations was USD 1.73 compared to USD 2.65 a year ago.

Latest news about Tricida, Inc.

Tricida, Inc. Went Out of Business	23-06-12	CI
First Motion for Exclusivity Period Extension Approved For Tricida, Inc.	23-06-01	CI
Fifth Amended Liquidation Plan Approved for Tricida, Inc.	23-05-23	CI
Fifth Amended Liquidation Plan Filed by Tricida, Inc.	23-05-22	CI
Fourth Amended Liquidation Plan Filed by Tricida, Inc.	23-05-12	CI
First Motion for Exclusivity Period Extension Filed by Tricida, Inc.	23-05-08	CI
North American Morning Briefing : China Data Helps -3-	23-04-18	DJ
North American Morning Briefing : Stock Futures -3-	23-04-11	DJ
Fourth Amended Disclosure Statement Approved for Tricida, Inc.	23-03-27	CI
Fourth Amended Disclosure Statement Filed by Tricida, Inc.	23-03-24	CI
Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-03-21	CI
Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-02-25	CI
First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-02-24	CI
Motion for Asset Sale Approved for Tricida, Inc.	23-02-21	CI
Motion for Asset Sale Approved for Tricida, Inc.	23-02-21	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	23-02-16	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	23-02-16	CI
Tricida, Inc. Announces Resignation of David Bonita as Director	23-01-27	CI
Bidding Procedure Approved for Tricida, Inc.	23-01-25	CI
Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index	23-01-23	CI
Top Premarket Gainers	23-01-18	MT
Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P TMI Index	23-01-18	CI
Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-01-17	CI
Tricida, Inc. Filed for Bankruptcy	23-01-11	CI
Motion for Asset Sale Filed by Tricida, Inc.	23-01-10	CI

Chart Tricida, Inc.

Duration

Period

More charts

Company Profile

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+69.56%	62.86B
IQVIA HOLDINGS INC.	-0.64%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+14.73%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.22%	18.9B
BIO-TECHNE CORPORATION	+4.87%	12.67B
UNITED THERAPEUTICS CORPORATION	+23.92%	12.27B
MEDPACE HOLDINGS, INC.	+28.11%	12.07B

Other Biotechnology & Medical Research